Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.
Crinetics Pharmaceuticals (CRNX) stock fell after Phase 2 results for its experimental drug atumelnant for congenital adrenal hyperplasia. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback